| http://www.w3.org/ns/prov#value | - Research and development expenses represented ???259.1 million in 2013, up 4.4% year-on-year, mainly driven by the major programmes conducted during the period on Dysport?? (spasticity of the lower and upper limbs), tasquinimod and Somatuline??.
|
